Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 693

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 693
---
,085 to reflect the increase in accounts payable and accrued expenses have been included in the pro forma condensed combined balance sheet as of December 31, 2024.

GRepresents the additional equity issued by Kineta in March 2025 after entering into a securities exchange agreement (the “Exchange Agreement”) with an existing investor (the “Holder”) pursuant to which Kineta agreed to issue an aggregate of (i) an aggregate of 1,225,323 shares of Kineta Common Stock, and (ii) a pre-funded warrant to purchase up to an aggregate of 655,019 shares of Kineta Common Stock, in exchange for certain outstanding warrants (the “Prior Warrants”) held by the Holder to purchase up to 2,315,387 Kineta shares (the “Exchange”). While the Exchange only has impacts to the stockholders’ equity of Kineta before the Closing Date of the Mergers, the adjustment is reflected in the pro forma condensed combined financial information as the terms of the Exchange Agreement also include provisions to ensure that the Holder will vote in favor of the approval of the transactions contemplated in the Merger Agreement.

The Prior Warrants as well as both the newly issued Kineta common shares and pre-funded warrants were determined to be equity-classified. Accordingly, the accounting for the exchange is recognized as a capital transaction with net zero impact to Kineta’s total equity. The 1,225,323 shares issued by Kineta in connection with the Exchange are reflected through the $1,225 adjustment to Kineta common stock recorded at par value, with $1,225 being recognized as the corresponding reduction to Kineta’s Additional paid-in capital in the pro forma condensed combined balance sheet as of December 31, 2024, as a result of the adjustment to Kineta’s outstanding common stock before the Mergers. All of the outstanding equity of Kineta at the Effective Time, including the shares issued pursuant to this Exchange Agreement, will be canceled and will cease to exist at the Effective Time in accordance with the Merger Agreement, only representing the right to receive the share of Merger Consideration (as stated in the Introduction). Refer to adjustment Ewhere the cancellation of the Kineta equity as of the Effective time is reflected in the pro forma condensed combined balance sheet as of December 31, 2024.

HRepresents the estimated $1,305,724 of Kineta transaction costs (refer to adjustment F1) that are expected to be paid in cash (or pre-Merger Kineta